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A coordinate deregulation of microRNAs
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colon cancer
Angela Grassi1*†, Lisa Perilli1,2*†, Laura Albertoni3, Sofia Tessarollo2, Claudia Mescoli3, Emanuele D. L. Urso4,
Matteo Fassan3, Massimo Rugge3 and Paola Zanovello1,2*
Abstract
Up to 20% of colorectal cancer (CRC) node-negative patients develop loco-regional or distant recurrences within 5
years from surgery. No predictive biomarker able to identify the node-negative subjects at high risk of relapse after
curative treatment is presently available.
Forty-eight localized (i.e. stage I-II) colon cancer patients who underwent radical tumor resection were considered.
The expression of five miRNAs, involved in CRC progression, was investigated by qRT-PCR in both tumor tissue and
matched normal colon mucosa.
Interestingly, we found that the coordinate deregulation of four miRNAs (i.e. miR-18a, miR-21, miR-182 and miR-183),
evaluated in the normal mucosa adjacent to tumor, is predictive of relapse within 55 months from curative surgery.
Our results, if confirmed in independent studies, may help to identify high-risk patients who could benefit most from
adjuvant therapy. Moreover, this work highlights the importance of extending the search for tissue biomarkers also to
the tumor-adjacent mucosa.
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Background
Colorectal cancer (CRC) is the third most common tumor
in the United States [1]. Up to 20% of node-negative (stage
I and stage II) patients develop loco-regional or distant
recurrences within 5 years from wide surgical resection
and anastomosis. No predictive biomarker able to identify
the node-negative subjects at high risk of relapse after
curative surgery is presently available. Adjuvant chemo-
therapy is considered for stage II patients with at least one
of the following clinical characteristics: sampling of fewer
than 12 lymph nodes during surgical resection; poorly
differentiated tumor; vascular, lymphatic or perineural
invasion; tumor presentation with obstruction or tumor
perforation and pT4 stage [2]. In this setting, the
identification of biomarkers to guide adjuvant therapy
decision could be extremely useful for clinical practice.
CRC develops and progresses through the accumulation
of alterations affecting both noncoding and coding RNAs.
Noncoding RNAs control multiple biological processes
and have emerged as possible biomarkers for the clinical
diagnosis and prognosis of CRC [3]. Different microRNA
(miRNA) expression patterns observed in primary CRC
have also been associated with tumor stage and patient
survival [4].
In previous work, we identified up- and down-regulated
miRNAs in primary colon carcinoma versus normal colon
mucosa samples from metastatic CRC patients and
reconstructed putative post-transcriptional regulatory
sub-networks involving the most differentially
expressed miRNAs and their target genes [5].
More recently, a study by Sanz-Pamplona and colleagues
demonstrated that a number of tumor-related genes were
activated in the tumor-adjacent non-neoplastic mucosa of
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Fig. 1 Boxplots of the distribution of –ΔCt values in tumor tissue versus matched normal mucosa for miR-18a, miR-21, miR-182, miR-183 and miR-139.
Each dot represents a patient sample. –ΔCt values were calculated using miR-200c as a reference. Differences between cancer tissue (K) and matched
normal mucosa (N) samples were analyzed using one-tailed Wilcoxon rank-sum test
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CRC patients. These activated genes were enriched in
transcription factors, indicating the existence of a transcrip-
tional program driving the observed altered expression
pattern in normal mucosa [6]. This result paves the way for
the possibility to detect tumor-specific alterations also in
the adjacent mucosa.
The focus of this paper is to identify miRNAs that
could serve as biomarkers of relapse after resection in
localized colon cancer, by investigating both matched
normal colon mucosa and tumor tissue, resected from
the surgical specimen.
Findings
In this study we explored the usefulness of a set of five
miRNAs (i.e. miR-18a, miR-21, miR-182, miR-183 and
miR-139) as biomarkers of relapse after primary tumor
resection in stage I-II colon cancer.
These miRNAs were already known to be involved in
CRC progression. In particular, miR-21 is a known
oncomiR, whose high expression levels have been related
to inflammation-associated colorectal tumorigenesis and
dismal clinical outcome [7]. MiR-18a was found to be
significantly up-regulated in patients with a form of
chronic inflammation, i.e. colonic polyps [8], and it has
been suggested as a prognostic factor for survival of post-
operative CRC patients [9]. The increased expression of
miR-183 and miR-182, both members of miR-183 cluster,
has been related to advanced clinical stage, lymph node
involvement, distant metastases and poor prognosis
[10, 11]. Concerning miR-139, a recent study highlighted
its down-regulation in colon cancer cell lines and patients
and its association with metastasis and drug
resistance [12].
Differentially expressed microRNAs in localized colon
cancer between tumor and matched normal mucosa
Forty-eight patients with sporadic stage I-II colon cancer
were considered and both tumor tissue and matched
normal mucosa were collected at the time of curative
surgery, see Additional file 1. The expression levels of
the five selected miRNAs, already known to be modulated
in advanced CRC (stage IV), were evaluated. Interestingly,
our analysis confirmed that they were all significantly
regulated in the early phases of the CRC tumor process.
Specifically, miR-18a, miR-21, miR-182 and miR-183 were
strongly up-regulated (p < < 0.001) in cancer tissue with
respect to normal mucosa, whereas miR-139 was strongly
down-regulated (p < < 0.001), see Fig. 1. This finding
extends to stage I-II CRC the results previously obtained
in stage IV CRC [5], showing that these five miRNAs
accompany the CRC tumor process, from initial stages to
advanced tumorigenesis.
To assess the role of tumor-associated inflammation in
the modulation of these miRNAs, we also evaluated their
expression levels in 10 patients affected by ulcerative col-
itis, a form of inflammatory bowel disease characterized
by chronic and widespread inflammation of the colorectal
mucosa. MiR-18a and miR-21 appeared weakly up-
regulated in the inflammatory tissue vs. normal mucosa
with p-value of 0.053 and 0.042, respectively. Conversely,
miR-182, miR-183 and miR-139 were not significantly
modulated (Additional file 1: Fig. S1). Although with a
limited sample size, our data indicate that the modulations
of miR-182, miR-183 and miR-139 are more specific of
the tumor process. MiR-18a and miR-21, instead, appear
weakly up-regulated also in inflamed bowel tissue, in line
with previously published works [7, 8], thus suggesting
that the strong up-regulation of these two miRNAs in the
tumor tissue could be partially related to inflammation.
miRNA ratios as possible biomarkers of relapse
Based on recurrence-free survival (RFS), the 48 localized
colon cancer patients in study were subdivided into a
recurrent group (R, 23 patients with RFS > 55) and a
non-recurrent group (NR, 25 patients with RFS < 55),
see Additional file 1. The clinical characteristics of the
patients are described in Table 1.
To investigate whether the selected miRNAs could be
useful to predict tumor relapse, we applied the miRNA
ratio approach [13, 14]. We calculated 10 ratios between
the expression values of all possible miRNA pair combina-
tions (see Additional file 1) in both the tumor tissue and
the adjacent normal mucosa, and assessed their capability
to predict relapse through univariate logistic regression
analysis, Additional file 1: Table S1. None of the miRNA ra-
tios resulted predictive when evaluated in the colon cancer
tissue. Three miRNA ratios, evaluated in the tumor-
adjacent mucosa, were found to be significant predictors of
relapse within 55 months from resection: miR-21/miR-183
(p = 0.0011), miR-18a/miR-182 (p = 0.0053) and miR-18a/
miR-183 (p = 0.0099), see Fig. 2a and Additional file 1:
Table S2 for details about univariate logistic regression
models. Corresponding areas under ROC curves were 0.83,
0.76 and 0.78, respectively, see Fig. 2b. It is noteworthy that
the three significant miRNA ratios (miR-21/miR-183,
miR-18a/miR-182 and miR-18a/miR-183) together with
miR-21/miR-182 ratio, which appears weakly signifi-
cant (p = 0.063, Additional file 1: Table S1), share a
common characteristic. These miRNA ratios have at nu-
merator a microRNA that in our setting appears associated
also to inflammation (either miR-18a or miR-21) and at de-
nominator a microRNA more specific of the tumor (either
miR-183 or miR-182). We thus conclude that a coordinate
deregulation of these two couples of miRNAs may be a
useful predictor of relapse. To investigate how the individ-
ual miRNAs perform as predictive biomarkers, an add-
itional univariate logistic regression analysis was executed
and reported in Additional file 1: Table S3, showing that
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the miRNA ratio approach yields to more significant re-
sults. Moreover, a bivariate logistic regression analysis, tak-
ing as covariates all the possible combinations of miRNA
pairs, was conducted (Additional file 1: Table S4). This
analysis confirmed that, regardless of the chosen approach,
it is the coordinated alteration of the two couples of miR-
NAs that we have identified to be predictive of relapse.
The advantage of the miRNA ratio approach is to over-
come the need for miR-200c as a normalizer.
More interestingly, the three significant miRNA ratios
seem to be potential biomarkers when evaluated in the
adjacent, morphologically normal, mucosa and not in
the tumor tissue. This result, apparently counterintui-
tive, is in line with recent gene expression studies on the
adjacent mucosa conducted both in CRC [6] and in head
and neck cancer [15]. Indeed, it is emerging with in-
creasing evidence that the crosstalk between tumor and
microenvironment could also affect the adjacent mucosa
and that also this tissue may be informative.
Conclusion
Our analysis showed that not a single miRNA, but rather
a coordinated alteration of four miRNAs (i.e. miR-18a,
miR-21, miR-182 and miR-183) may be useful to predict
recurrence after curative surgery. This is the first study
that outlines a predictive role of miRNAs, evaluated in
the adjacent, morphologically normal, mucosa of CRCs.
Our results, if confirmed in an ample cohort of patients,
may help to identify among localized colon cancer (stage
I-II) patients those at high risk of relapse who could
benefit most from adjuvant therapy.
Additional file
Additional file 1: Supplementary information including Materials and
Methods, Tables S1-S4 and Figure S1. (PDF 157 kb)
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Table 1 Clinical characteristics of relapsing (R) and non-
relapsing (NR) patients
Characteristics R NR
n = 23 n = 25
Age at resection
(years)
Median 72 69
Range 55–85 50–90
Sex M 16 (70%) 10 (40%)
F 7 (30%) 15 (60%)
Tumor site Cecum, colon ascending,
hepatic (right) flexure
7 6
transverse colon 3 4
Splenic (left) flexure, colon
descending, sigmoid colon
13 15
Rectum 0 0
TNM stage I 6 7
II 17 18
T(n) T1 2 1
T2 4 6
T3 15 18
T4 2 0
N(n) N0 23(100%) 25(100%)
M(n) M0 23 (100%) 25 (100%)
Grading (n) G1 5 4
G2 15 17
G3 3 4
G4 0 0
Fig. 2 miR-21/miR-183, miR-18a/182 and miR-18a/183 ratios in tumor-adjacent mucosa predict relapse of colon cancer after bowel resection.
a. The three panels show the distribution of miRNA ratio relative expression levels, indicated as 2-ΔCt, in localized colon cancer patients, relapsing
(R) and non-relapsing (NR) within 55 months after resection. b. ROC curves generated for the three significant miRNA ratios (p < 0.01) in univariate
logistic regression. Corresponding areas under ROC curves (AUC) are detailed in the figure
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